Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
9.97
-0.10 (-0.99%)
Jul 29, 2026, 4:00 PM EDT - Market closed
Keros Therapeutics Employees
Keros Therapeutics had 87 employees as of March 31, 2026. The number of employees increased by 9 or 11.54% since the number was last reported on December 31, 2025.
Employees
87
Change
9
Growth
11.54%
Revenue / Employee
$381,402
Profits / Employee
-$978,678
Market Cap
197.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 87 | 9 | 11.54% |
| Dec 31, 2025 | 78 | -91 | -53.85% |
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Protalix BioTherapeutics | 226 |
| Entrada Therapeutics | 152 |
| MediWound | 121 |
| NovaBridge Biosciences | 30 |
| Whitehawk Therapeutics | 29 |
| Greenwich LifeSciences | 8 |
| Minerva Neurosciences | 7 |
KROS News
- 4 weeks ago - Keros Therapeutics Appoints Anne Prener to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Keros Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c) - TheFly
- 2 months ago - Keros Therapeutics Reports Recent First Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - Keros Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Keros Therapeutics Quarterly report: Q1 2026 - Filings
- 3 months ago - Keros Therapeutics Proxy statement: Proxy filing - Filings